Certainty of evidence

How confident researchers are that a result is true, often graded high, moderate, low or very low. 'Very low certainty' means future research could easily change the answer.

Also called: quality of evidence, grade, evidence grade, low certainty, high certainty, level of evidence

Related words systematic review guideline

Topics Research

Questions people ask

What is a Cochrane review and why does it matter?

Cochrane reviews are systematic reviews: researchers find every good trial on a question, judge how reliable each one is and combine the results. They also grade how certain the evidence is. For Crohn's, Cochrane has found strong evidence for some treatments, such as vedolizumab, and too little evidence to judge others, such as treatments for fatigue.

Sources

Can I have treatment for piles if I have Crohn's?

Piles can be treated, but surgery needs care. A 2022 review of studies on piles surgery in people with IBD found the evidence was low quality and concluded that operations in Crohn's should be done cautiously, after other treatments have failed and when the disease is inactive. The NHS describes self-care and pharmacy options for piles; talk to your IBD team before any procedure.

Sources

Where to read more

British Society of Gastroenterology guidelines on inflammatory bowel disease in adults: 2025

British Society of Gastroenterology Guideline Jun 2025 For professionals

The current UK specialist guideline for managing IBD in adults, replacing the 2019 version. It is designed to sit alongside the IBD Standards and encourage use of the national primary care pathway for lower gut symptoms so diagnosis is quicker and more accurate. Among its general principles, it recommends classifying Crohn's using the Montreal system.

Topics About Crohn's disease Diagnosis and tests Medicines Monitoring Complications Surgery

Jargon explained Montreal classification remission endoscopic remission inflammatory bowel disease advanced therapy GRADE induction maintenance

ECCO Guidelines on Therapeutics in Crohn's Disease: Medical Treatment

European Crohn's and Colitis Organisation (J Crohns Colitis) Guideline Oct 2024 For professionals

Europe's main expert guideline on which medicines to use for Crohn's disease, published as the first of a two-part set (the second covers surgery). It weighs up the trial evidence for steroids, immunosuppressants, biologics and newer tablets, including treatment of disease around the back passage. UK specialists use it alongside the BSG guideline.

Topics Medicines Biologics and newer medicines Immunosuppressants Around the bottom (perianal)

Jargon explained biologic immunomodulator induction maintenance de-escalation perianal fistula GRADE

AGA Clinical Practice Guidelines on the Medical Management of Moderate to Severe Luminal and Perianal Fistulizing Crohn's Disease

American Gastroenterological Association (Gastroenterology) Guideline Jun 2021 For professionals

The American Gastroenterological Association's guideline on medicines for moderate to severe Crohn's, including fistulas around the anus. It rates the strength of evidence behind each drug option. It is American, so some drug choices and approvals differ from the NHS, but it is free to read in full and widely cited.

Topics Medicines Biologics and newer medicines Around the bottom (perianal)

Jargon explained luminal perianal fistulizing certainty of evidence

Anti-IL-12/23p40 antibodies for induction of remission in Crohn's disease

Cochrane Systematic review May 2025 Patients and professionals

Updated Cochrane review of ustekinumab (Stelara) and related drugs for active Crohn's. It found ustekinumab helps bring on remission by eight weeks and probably does not cause more serious side effects than placebo. There was not enough data to choose the best dose for children, and comparisons with other biologics are very uncertain.

Topics Biologics and newer medicines

Jargon explained IL-12/23 induction certainty of evidence

Vedolizumab for induction and maintenance of remission in Crohn's disease

Cochrane Systematic review Jul 2023 Patients and professionals

Pooling several trials, Cochrane found high-certainty evidence that vedolizumab (Entyvio) works better than placebo both for bringing on remission and keeping it. Overall side effects were probably similar to placebo. Head-to-head comparisons with other biologics are still needed.

Topics Biologics and newer medicines Research

Jargon explained high-certainty evidence induction maintenance integrin

Azathioprine and 6-mercaptopurine for maintenance of surgically-induced remission in Crohn's disease

Cochrane Systematic review Aug 2019 Patients and professionals

Looks at whether azathioprine or mercaptopurine help stop Crohn's coming back after an operation. The evidence is weak: they may be a little better than placebo, may cause more side effects than mesalazine-type drugs, and may be less effective than anti-TNF biologics, but no firm conclusions can be drawn.

Topics Immunosuppressants Surgery Research

Jargon explained postoperative recurrence low certainty evidence post-operative recurrence thiopurine 5-ASA anti-TNF

Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn's disease

Cochrane Systematic review Oct 2015 Patients and professionals

Cochrane pooled the trials of azathioprine and mercaptopurine for keeping Crohn's quiet. Low-quality evidence suggests azathioprine works better than placebo, but side effects such as pancreatitis, low white cell counts, sickness and infections limit its use. More good-quality trials are needed.

Topics Immunosuppressants Research

Jargon explained thiopurine low-quality evidence adverse event remission placebo systematic review

Methotrexate for maintenance of remission in Crohn's disease

Cochrane (via PMC) Systematic review Aug 2014 Patients and professionals

A Cochrane review finding moderate-quality evidence that methotrexate given by injection helps keep Crohn's in remission and appears safe, while low-dose tablets did not appear effective in the trials reviewed. Adding methotrexate to infliximab did not improve remission rates.

Topics Immunosuppressants Research

Jargon explained methotrexate intramuscular maintenance

Search everything for "certainty of evidence"